%s1 / %s2

Playlist: Sunvalley Communication, LLC

Compiled By: Peter Hofland

 Credit:
No text

The OncoZine Brief (Series)

Produced by Peter Hofland

Most recent piece in this series:

Major Inprovements in Cancer Treatment Help Solve the Problem of Health Related Disparities

From Peter Hofland | Part of the The OncoZine Brief series | 40:00

Oncozine_finallogo01a_small In this Edition of the Onco’Zine Brief, Peter Hofland and Shelly Reynolds bring you a short interview with Dr. Otis Brawley, the chief medical and scientific officer of the American Cancer Society, recorded during the 2018 Annual Meeting of the American Society of Clinical Oncology.  In this interview they talk about some of the most exciting studies and research findings presented during this meeting.

Hofland and Reynolds also bring you a short interview with researchers from the University of Johannesburg in South Africa with Professor Reinout Meijboom, Head of the Department of Chemistry at the University of Johannesburg and Professor Marianne Cronjé, Head of the Department of Biochemistry at the University of Johannesburg.  In this interview they talk about the discovery of a new kind of drug that may greatly advance the treatment of various cancers currently treated with platinum based chemotherapeutic drugs, such as Cisplatin.

In the last part of the program they talk about ‘financial toxicity’ in the treatment of cancer. 

Based on a study published in the journal of Cancer, a peer-reviewed journal of the American Cancer Society, they explain  what Financial Toxicity is and what it means for Cancer Patients.  They also talk about the fact that many patients feel that such ‘financial toxicity’ is not adequately addressed by their doctors and other clinicians.

To investigate whether patients today are being helped by their doctors or staff with these challenges, Dr. Reshma Jagsi of the University of Michigan in Ann Arbor, and her colleagues surveyed patients with early-stage breast cancer and their physicians. The authors of the article conclude that greater efforts are indeed needed to address ‘financial toxicity’ of cancer treatment.